Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.12 per share versus the Zacks Co

Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million

Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.12) per share which missed the anal

Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5

SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or

Newtown Square, Pennsylvania--(Newsfile Corp. - May 27, 2026) - Kaskela Law LLC is investigating Gyr

GYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.

Gyre Therapeutics, Inc. ("Gyre", "Gyre Therapeutics" or the "Company") (NASD

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or

Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.05 per share versus the Zacks Co

Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million

Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.04) per share which beat the analys

Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5

Post-closing combined company has revenue-producing commercial asset and a robust pipeline of produc

Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (NASDAQ:GYRE), a San Diego-based innovative comm

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (N

Gyre Therapeutics, Inc. (GYRE) came out with quarterly earnings of $0.04 per share, missing the Zack

Gyre Therapeutics (NASDAQ:GYRE) sees FY2026 sales of $100.500 million-$111.000 million vs $146.133 m

Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.05 per share which missed the anal

Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range

Tenax Therapeutics (NASDAQ: TENX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free R

Gyre Therapeutics, Inc. (Gyre or the Company) (NASDAQ:GYRE), an innovative, commercial-stage biophar

Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with reve

ImmunityBio (NASDAQ: IBRX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free Report)

Gyre Pharmaceuticals completed a Pre-NDA meeting with China's CDE, which agreed that the existin

Gyre Pharmaceuticals completed a Pre-NDA meeting with China's CDE, which agreed that the existing Ph

Gyre Therapeutics, Inc. (GYRE) came out with quarterly earnings of $0.06 per share, beating the Zack

Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.03 per share which beat the analys

Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025,

GYRE, DAR and CRLBF have been added to the Zacks Rank #5 (Strong Sell) List on October 17, 2025.

A total of 272 patients have been enrolled in this multicenter, randomized, double-blind, placebo-co

SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commer

Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical

Jefferies analyst Roger Song initiates coverage on Gyre Therapeutics (NASDAQ:GYRE) with a Buy rat

HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billi

HC Wainwright & Co. analyst Matthew Keller initiates coverage on Gyre Therapeutics (NASDAQ:GY

Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 2

Gyre Therapeutics (NASDAQ:GYRE) reported quarterly sales of $22.06 million which missed the analyst